Equities Analysts Issue Forecasts for KalVista Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Leerink Partnrs issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz expects that the specialty pharmaceutical company will post earnings of ($0.72) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($2.83) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09).

A number of other equities analysts have also recently issued reports on KALV. HC Wainwright upped their price target on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, April 11th.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $11.57 on Thursday. The stock has a market cap of $488.14 million, a price-to-earnings ratio of -3.67 and a beta of 0.88. The firm’s 50-day moving average is $12.69 and its 200 day moving average is $11.26. KalVista Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $16.88.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 20,686 shares of the firm’s stock in a transaction on Wednesday, January 24th. The stock was acquired at an average price of $12.44 per share, with a total value of $257,333.84. Following the transaction, the insider now owns 4,558,780 shares in the company, valued at $56,711,223.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 20,686 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, January 24th. The stock was purchased at an average price of $12.44 per share, with a total value of $257,333.84. Following the transaction, the insider now directly owns 4,558,780 shares of the company’s stock, valued at $56,711,223.20. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Edward P. Feener sold 28,288 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $14.07, for a total transaction of $398,012.16. Following the sale, the insider now directly owns 62,157 shares of the company’s stock, valued at approximately $874,548.99. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 207,227 shares of company stock valued at $2,808,574 and sold 75,978 shares valued at $1,070,918. 12.30% of the stock is owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC increased its position in shares of KalVista Pharmaceuticals by 5.1% during the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after purchasing an additional 6,670 shares during the last quarter. Vanguard Group Inc. increased its position in shares of KalVista Pharmaceuticals by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock valued at $16,684,000 after purchasing an additional 151,808 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $49,000. New York State Common Retirement Fund increased its holdings in KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 9,451 shares in the last quarter. Finally, Strs Ohio purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter worth approximately $104,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.